P394: Frontline Combination of Olverembatinib and PDT-All-2016 Pediatric Inspired Protocol in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Abstract

Tyrosine kinase inhibitors (TKIs) combined standard chemotherapy have improved the long-term outcomes of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Previous studied showed that ponatinib, combined with Hyper-CVAD, result in modest rates of complete molecular response (CMR) of 75% in three months. Olverembatinib, a new potent third-generation TKI, shows well tolerated and significant-activity in patients with TKI-resistant CML but marginally analyzed in ALL.